-
1.发明申请公开(公告)号：US20210000792A1
公开(公告)日：2021-01-07
申请号：US17021370
申请日：2020-09-15
IPC分类号： A61K31/381 , A61P9/00 , A61P3/00 , A61K31/7042
摘要： The present invention is directed to methods for reducing, preventing or slowing the progression of cardiovascular risk factors and/or cardiovascular disease, comprising administration of canagliflozin.
-
2.发明申请公开(公告)号：US20180353470A1
公开(公告)日：2018-12-13
申请号：US16004607
申请日：2018-06-11
IPC分类号： A61K31/381 , A61P3/00 , A61P9/00
CPC分类号： A61K31/381 , A61K31/7042 , A61P3/00 , A61P9/00
摘要： The present invention is directed to methods for reducing, preventing or slowing the progression of cardiovascular risk factors and/or cardiovascular disease, comprising administration of canagliflozin.
-
公开(公告)号：US11207337B2
公开(公告)日：2021-12-28
申请号：US16820767
申请日：2020-03-17
IPC分类号： A61K31/7042 , A61K31/135 , A61K31/137
摘要： The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.
-
4.发明申请公开(公告)号：US20200215090A1
公开(公告)日：2020-07-09
申请号：US16820767
申请日：2020-03-17
IPC分类号： A61K31/7042 , A61K31/137 , A61K31/135
摘要： The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.
-
公开(公告)号：US20220160739A1
公开(公告)日：2022-05-26
申请号：US17440990
申请日：2020-03-25
发明人： Norman R. Rosenthal
IPC分类号： A61K31/7042 , A61K45/06 , A61P13/12 , A61P3/10
摘要： The present disclosure provides methods for treating chronic kidney disease, comprising administering to a patient in need thereof, a therapeutically effective amount of canagliflozin; wherein the patient is diagnosed with Type II diabetes mellitus.
-
6.发明申请公开(公告)号：US20190142855A1
公开(公告)日：2019-05-16
申请号：US16245682
申请日：2019-01-11
IPC分类号： A61K31/7042 , A61K31/135 , A61K31/137
摘要： The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.
-
7.发明申请CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS 审中-公开用于治疗肥胖和肥胖相关疾病的卡尼普利嗪和苯那司敏联合治疗公开(公告)号：US20170071970A1
公开(公告)日：2017-03-16
申请号：US15262038
申请日：2016-09-12
IPC分类号： A61K31/7042 , A61K31/135
CPC分类号： A61K31/7042 , A61K31/135 , A61K31/137 , A61K2300/00
摘要： The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.
摘要翻译： 本发明涉及包括给予canagliflozin和phentermine治疗肥胖症和肥胖相关疾病的协同治疗的用途。 更具体地，本发明涉及用于治疗肥胖症，促进体重减轻和/或抑制食欲的共同治疗; 用于治疗，延缓，减缓代谢紊乱（包括例如2型糖尿病）的进展和/或预防; 用于治疗，延缓，减缓肾或脂肪性肝病的进展和/或预防（或包括例如NASH，NAFLD等）; 用于治疗，延迟，减缓睡眠障碍（包括例如睡眠呼吸暂停）的进展和/或预防和/或预防睡眠障碍。 用于提供心血管保护; 用于治疗，延迟，减缓心血管事件进展和/或预防心血管事件（包括主要不良心脏事件（MACE）），如心肌梗塞，不稳定型心绞痛，心血管死亡，血运重建，致命或非致命性脑血管意外，外周动脉病变，主动脉事件 ，由于充血性心力衰竭住院治疗等）; 和/或用于延长或延长使用寿命。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.014 秒)
